---
figid: PMC5797008__oncotarget-09-4722-g005
figtitle: Activation of MAPK signalling results in resistance to saracatinib (AZD0530)
  in ovarian cancer
organisms:
- NA
pmcid: PMC5797008
filename: oncotarget-09-4722-g005.jpg
figlink: /pmc/articles/PMC5797008/figure/F5/
number: F5
caption: 'Left: In saracatinib (AZD0530) sensitive cells, inhibition of SRC leads
  to a reduction in the ability of SRC to phosphorylate and activate downstream signalling
  pathways resulting in decrease proliferation, migration, invasion angiogenesis and
  cell death. Right: In saracatinib (AZD0530) resistant cells, increased expression
  and activation of HER2 and the insulin receptor drives the activation of the RAS-RAF-MAPK
  pathway. Loss or reduction in the expression of the tumour suppressor gene NF1 also
  releases the negative regulation of RAS-RAF MAPK pathways allowing for MAPK induced
  cell survival and drug resistance.'
papertitle: Activation of MAPK signalling results in resistance to saracatinib (AZD0530)
  in ovarian cancer.
reftext: Niamh McGivern, et al. Oncotarget. 2018 Jan 12;9(4):4722-4736.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9743677
figid_alias: PMC5797008__F5
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC5797008__F5
ndex: 07c7c119-dec0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5797008__oncotarget-09-4722-g005.html
  '@type': Dataset
  description: 'Left: In saracatinib (AZD0530) sensitive cells, inhibition of SRC
    leads to a reduction in the ability of SRC to phosphorylate and activate downstream
    signalling pathways resulting in decrease proliferation, migration, invasion angiogenesis
    and cell death. Right: In saracatinib (AZD0530) resistant cells, increased expression
    and activation of HER2 and the insulin receptor drives the activation of the RAS-RAF-MAPK
    pathway. Loss or reduction in the expression of the tumour suppressor gene NF1
    also releases the negative regulation of RAS-RAF MAPK pathways allowing for MAPK
    induced cell survival and drug resistance.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - scb
  - Fak
  - Src42A
  - Csk
  - Src64B
  - Nf1
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - ERBB2
  - IGF2
  - ITGA1
  - ITGA10
  - ITGA11
  - ITGA2
  - ITGA2B
  - ITGA3
  - ITGA4
  - ITGA5
  - ITGA6
  - ITGA7
  - ITGA8
  - ITGA9
  - ITGAD
  - ITGAE
  - ITGAL
  - ITGAM
  - ITGAV
  - ITGAX
  - ITGB1
  - ITGB2
  - ITGB3
  - ITGB4
  - ITGB5
  - ITGB6
  - ITGB7
  - ITGB8
  - ITGBL1
  - PTK2
  - SRC
  - FGR
  - FYN
  - YES1
  - NF1
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - AZD0530
  - Tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
